,
your personalized virtual assistant to find clinical trials. Go head, 
Barbara Fussell, RN
Institute for Neurodegenerative DisordersNew haven, Connecticut - 06510 (203 401 4362) |
- CLINICAL TRIALS 6
- CONDITIONS8
- INTERVENTIONS5
- SINCE2003
Evaluation of [123I]MNI-420 and Single Photon Emission Computed Tomography (SPECT) as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease (PD) and Huntington Disease (HD)
July 2009 - July 2010
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
September 2010 - February 2011
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
May 2003 - January 2013
Study to Identify Clinical Imaging and Biologic Markers of Parkinson Disease Progression
June 2010 - December 2017
A PET Brain Imaging Study of mGluR5 in Subjects With PD HD FXS & ASD
March 2009 - March 2011
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
March 2010 - November 2010
Alzheimer Disease
Parkinson Disease
Autistic Disorder
Child Development Disorders, Pervasive
Huntington Disease
Parkinsonian Disorders
Disease Progression
Fragile X Syndrome
[123i]Mni-420
[18f] Mni-558
Automated Neuropsychological Assessment Matrix
(18f)Fpeb
Drug: [18f] Pbr111
